Drawings




Fig. 1




Fig. 2



OD (450-650)
4
3
2
1
0
1e-2
1e-1
1e0
1e1
1e2
1e3
1e4
1e5
1e6
Concentration (ng/ml)

Fig. 3



OD (450-650)
1.5
1
0.5
0
1e-1
1e0
1e1
1e2
1e3
1e4
1e5
1e6
1e7
Concentration (ng/ml)

Fig. 4



OD (450-650)
4
3
2
1
0
1e0
1e1
1e2
1e3
1e4
1e5
1e6
1e7
Concentration (ng/ml)

Fig. 5



OD (450-650)
1
0.5
0
1e-1
1e0
1e1
1e2
1e3
1e4
1e5
1e6
Concentration (ng/ml)

Fig. 6



Dilution buffer IV Day1,5,9,13
BA03 5mg/kg IV Day1,5,9,13
MYK-3 1mg/kg IV Day1,5,9,13
MYK-3 5mg/kg IV Day1,5,9,13
Non-binding ADC 5mg/kg IV Day1,5,9,13
Tumor volume (mm3)
Date after administration (days)
2500
2000
1500
1000
500
0
0 3 6 9 12 15 18 21 24 27 30 33 36
*
**
**
**
**

Fig. 7



dilution buffer IV Day1,5,9,13
BA03 mAb 5mg/kg IV Day1,5,9,13
MYK-3 1mg/kg IV Day1,5,9,13
MYK-3 5mg/kg IV Day1,5,9,13
Non-binding ADC 5mg/kg IV Day 1, 5, 9, 13
Body weight (g)
Date after administration (Days)
25.00
20.00
15.00
10.00
5.00
0.00
0 3 6 9 12 15 18 21 24 27 30 33 36

Fig. 8





dilution buffer IV Day 1,5,9,13
Erbitux 3mg/kg IV Day1,5,9,13
MYK-3 0.3mg/kg IV Day1,5,9,13
MYK-3 1mg/kg IV Day1,5,9,13
MYK-3 3mg/kg IV Day1,5,9,13
Non-binding ADC 3mg/kg IV Day 1,5,9,13
Tumor volume (mm³)
Date after administration (Days)
0
500
1000
1500
2000
2500
3000
0
3
6
9
12
15
18
21
24
27
30
33
36
39


Fig. 9


The trend of HMW changes in formulations with different pH at 40 ° C
HMW (%)
Time (days)
pH6.0
pH6.3
pH6.5
pH6.7

a


The trend of acidic peak changes in formulations with different pH at 40℃
Acidic peak (%)
T (Days)
pH6.0
pH6.3
pH6.5
pH6.7

b


The trend of DAR changes in formulations with different pH at 40℃
DAR
T (Days)
pH6.0
pH6.3
pH6.5
pH6.7

c

Fig. 10